Overview

Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Status:
Terminated

Trial end date:
2010-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety and preliminary effectiveness of ixabepilone plus lapatinib with and without capecitabine in the treatment of human epidermal growth factor receptor 2 (HER2)-positive or metastatic breast cancer.

Phase:

Phase 1

Details

Lead Sponsor:

R-Pharm

Collaborator:

GlaxoSmithKline

Treatments:

Capecitabine
Epothilones
Lapatinib